HSTalks

Antibodies: Structure, Engineering, and Therapeutics This learning journey is designed to provide an introduction to the structural composition of


immunoglobulins, antibody engineering methods,

and their therapeutic applications. Several key antibody concepts are covered including classification, discovery, clinical relevance, and immunogenicity.

Extract from: **Antibody Structure** 'Antibody structure and function:

An Introduction to Antibodies

and their Structure



and Function

Dr. Mike Clark – University of Cambridge, UK **10 mins** (00:24 - 10:59)

Extract from:


antibody structure'

12 mins (19:17 - 31:30)

antibody structure'

'Antibody structure and function: Dr. Mike Clark – University of Cambridge, UK

Antibody Classes and Subclasses



Antibody Structure

and Function

Part 1 of 2 - Antibody Structure

Dr. Mike Clark FRSB

Antibody Valency and Function

Extract from:

Extract from:

3 mins (00:28 - 04:00)

UK

antibody structure'


11 mins (00:42 - 18:28)

Dr. Mike Clark FRSB erly Reader in Therapeutic and Molecular Immunology Department of Pathology Cambridge University, UK

Antibody Structure

and Function

Part 2 of 2 - Antibody Function



The Immunobiology

of Fc Receptors

Professor Mark Cragg, PhD Professor of Experimental Cancer Biolo Antibody and Vaccine Group

Antibody Receptors (FcRs)

'The immunobiology of Fc receptors'

Prof. Mark Cragg – University of Southampton,

The Role and Structure of

'Antibody structure and function:

Dr. Mike Clark – University of Cambridge, UK

'Antibody engineering: beginnings to

Dr. Ian Wilkinson – Absolute Antibody, UK

bispecifics and beyond'

8 mins (06:12 - 14:49)

Extract from:



Antibody engineering:

Beginnings to bispecifics and beyond

Dr. Ian Wilkinson Chief Scientific Offic Absolute Antibody



Antibodies

of Executive Officer of mAbsolve Ltd. rly Professor of Therapeutic II liam Dunn School of Patholo sity of Oxford, UK

Antibody Phage Display

Co-founder and CSO, YUMAB GMBH,

Extract from:

Dr. Geoffrey Hale – Chief Executive Officer of

'Therapeutic antibodies'

mAbsolve Ltd., UK

9 mins (10:20 - 20:00)

Genetic Engineering of Antibodies

The use of Antibodies for Cancer Treatment

Extract from: Phage Display 'Phage display for generating monoclonal for Generating antibodies' Monoclonal Antibodies Dr. Andre Frenzel – YUMAB GMBH, Germany Dr. Andre Frenzel, PhD

5 mins (12:26 - 18:20)

Extract from:

Southampton, UK

9 mins (01:42 - 11:14)

3 mins (36:06 - 39:18)


Extract from:

8 mins (12:02 - 20:34)

diabetes'

Belgium

oncology'



Antibodies for the Treatment

of Cancer: Herceptin

Monoclonal Antibodies and the ErbB System

Prof. Mark I. Greene MD, PhD, FRCP

Antibodies to Control or Prevent Type 1 Diabetes

Dr. Robert Hilbrands, MD, PhD

Diabetesclinic UZBrussel Brussels Free University (VUB)

in Human Cancer

Extract from: 'Monoclonal antibodies and the ErbB system in human cancer' Prof. Mark Greene – University of Pennsylvania, USA

'Antibodies to control or prevent type 1

Dr. Robert Hilbrands – Brussels Free University,

Monoclonal Antibodies for the

Treatment of Type-1 Diabetes

'Monoclonal antibodies in haemato-

Prof. Mark Cragg – University of

Extract from:

monoclonal antibodies'

4 mins (03:16 - 08:05)

10 mins (00:45 - 11:00)

Tolerance Induction to **Clotting Factors with** Monoclonal Antibodies

> **Antibody Therapy** Immunogenicity 'The immunogenicity problem in antibody

'Tolerance induction to clotting factors with

Prof. Luis Graca – University of Lisbon, Portugal

Antibodies for Transplant Tolerance

'Pathogenic mechanisms of autoantibodies: circulating and local antibodies that form

Dr. Luís Eduardo Coelho Andrade – UNIFESP,

Can Humanised Antibodies Reduce Immunogenicity?

mAbsolve Ltd., UK

The Immunogenicity Problem

in Antibody Therapy

Prof. Herman Waldmann Department of Pathology. Oxford University, UK

Autoantibodies and

Autoimmune Diseases

Pathogenic Mechanisms

of Autoantibodies

Part 1 of 2: Circulating and local antibodies that form immune complexes

Medical Consultant in Immunology Fleury Medicine & Health Laborato

Dr. Luís Eduardo Coelho Andrade, MD, PhD Associate Professor, Rheun UNIFESP, São Paulo, Bracil

therapy' Prof. Herman Waldmann - University of Oxford, UK

Extract from:

immune complexes'

4 mins (02:39 - 07:00)

São Paulo, Brazil

Whole talk:

Therapeutic Antibodies Chief Executive Officer of mAbsolve Ltd. erly Professor of Therapeutic In Sir William Dunn School of Pathology University of Oxford, UK

'Therapeutic antibodies' Dr. Geoffrey Hale – Chief Executive Officer of **4 mins** (21:04 - 26:39)